# Tudriqev (vusolimogene oderparepvec-wtpg) by Replimune, Inc.: new human prescription drug listing

**Launch Signal Score:** 80/100

| Field | Value |
|---|---|
| Product | Tudriqev |
| Generic name | vusolimogene oderparepvec-wtpg |
| NDC | 83616-107 |
| Labeler | Replimune, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Approval pathway | BLA |
| Application number | BLA125827 |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRATUMOR |
| Active ingredients | VUSOLIMOGENE ODERPAREPVEC 10000000 [PFU]/mL |
| Marketing start | 2026-09-04 |
| Package configurations | 1 |

## Why this score
- Prescription or biologic product.
- Brand or biologic launch.
- Injectable: hospital and 503B relevance.

Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=83616-107). Last refreshed: 2026-11-04T18:12:05.743Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.